This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Express Scripts Introduces Medicare PDP Offerings for 2019
by Zacks Equity Research
Express Scripts' (ESRX) Medicare PDP to initiate coverage from Jan 1, 2019. The plan includes Walmart along with CVS Pharmacy and the Kroger Family of Pharmacies.
Express Scripts' Accredo & Akcea Tie Up to Distribute TEGSEDI
by Zacks Equity Research
Express Scripts (ESRX) likely to gain market traction through distribution of TEGSEDI.
Cigna Gets Merger Nod, Forms Management for Unified Entity
by Zacks Equity Research
Cigna (CI) forms management as it prepares for new merged entity.
Aetna a Step Closer to CVS Merger, Sells Medicare Business
by Zacks Equity Research
Aetna (AET) gets a step closer to its merger with CVS Health by selling its Medicare business to WellCare Health.
Bull of the Day: Cigna (CI)
by Ryan McQueeney
Play this insurance giant ahead of its mega merger.
Cigna Moves Closer to Express Scripts Buyout With DoJ Nod
by Zacks Equity Research
Cigna (CI) clears a significant regulatory hurdle with regards to its proposed acquisition of Express Scripts.
Express Scripts (ESRX) Up 13.2% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Express Scripts (ESRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Options Traders Expect Huge Moves in Express Scripts (ESRX) Stock
by Zacks Equity Research
Express Scripts (ESRX) needs investors to pay close attention to the stock based on moves in the options market lately.
Regeneron (REGN) Q2 Earnings Beat on Strong Dupixent Sales
by Zacks Equity Research
Regeneron (REGN) reports impressive Q2 results on the back of growth in both Eylea and Dupixent sales.
Express Scripts (ESRX) Q2 Earnings Beat, Network Claims Fall
by Zacks Equity Research
Express Scripts (ESRX) witnesses year-over-year decline in adjusted network claims in Q2, thanks to the loss of certain public sector clients.
Express Scripts (ESRX) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Express Scripts (ESRX) delivered earnings and revenue surprises of 0.91% and 1.12%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Will Revenue, Membership Growth Aid Cigna (CI) Q2 Earnings?
by Zacks Equity Research
Cigna (CI) Q2 earnings is likely to gain from strong growth at its segments.
Will a Decline in Membership Mar Aetna's (AET) Q2 Earnings?
by Zacks Equity Research
Aetna (AET) Q2 earnings to suffer from lower membership and revenues partly offset by a lower tax rate.
Medical Stock Q2 Earnings Due on Aug 1: ESRX, DVA & HUM
by Zacks Equity Research
Solid R&D prospects likely to drive the healthcare industry in Q2 earnings.
Can PBM Unit Boost Express Scripts' (ESRX) Q2 Earnings?
by Zacks Equity Research
Strong performance by the PBM unit is likely to drive Express Scripts' (ESRX) top line in Q2. Home-delivery pharmacy care, specialty pharmacy care and drug data analysis services buoy optimism.
M&A Hits Record in 1H: Ride High With These ETFs
by Sweta Killa
Merger and acquisition activities across the globe hit record highs in the first half of 2018 driven by growing ambition of American companies.
New Strong Sell Stocks for June 22nd
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Walgreens-GE Faceoff: How Impactful is it for Dow Investors?
by Urmimala Biswas
The stock performance of Walgreens Boots (WBA) currently does not offer much conviction. Over the past year, shares show a decline of 17.9%.
New Strong Sell Stocks for June 20th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Here's Why You Should Steer Clear of Express Scripts for Now
by Zacks Equity Research
Express Scripts' (ESRX) loss of major customers, downbeat 2018 earnings guidance and selling of shares to Cigna make it lower its credibility as an investment pick.
Express Scripts' Inside Rx to Cut Medical Costs for the Aged
by Zacks Equity Research
Express Scripts (ESRX) keeps its commitment towards patient benefit management through subsidiary Inside Rx.
Express Scripts (ESRX) Up 2.9% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Express Scripts (ESRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Health Insurance Industry Outlook - May 2018
by Zacks Equity Research
Higher medical enrollment, surging revenues, medical cost management and an increasing share of revenues from complementary services helped results.
Is IQ Merger Arbitrage ETF (MNA) a Hot ETF Right Now?
by Sweta Killa
Smart Beta ETF report for MNA
Express Scripts (ESRX) Q1 Earnings Top, Patient Claims Fall
by Zacks Equity Research
Express Scripts (ESRX) witnesses year-over-year declines in patient claims in Q1, thanks to the loss of certain public sector clients.